210 related articles for article (PubMed ID: 22642738)
41. Panniculitis and lipoatrophy after subcutaneous injection of interferon beta-1b in a patient with multiple sclerosis.
O'Sullivan SS; Cronin EM; Sweeney BJ; Bourke JF; Fitzgibbon J
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1382-3. PubMed ID: 16782776
[No Abstract] [Full Text] [Related]
42. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
[TBL] [Abstract][Full Text] [Related]
43. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Ebers GC; Traboulsee A; Li D; Langdon D; Reder AT; Goodin DS; Bogumil T; Beckmann K; Wolf C; Konieczny A;
J Neurol Neurosurg Psychiatry; 2010 Aug; 81(8):907-12. PubMed ID: 20562430
[TBL] [Abstract][Full Text] [Related]
44. Abdominal wall ulceration and mucinosis secondary to recombinant human interferon-beta-1b.
Wells J; Kossard S; McGrath M
Australas J Dermatol; 2005 Aug; 46(3):202-4. PubMed ID: 16008658
[TBL] [Abstract][Full Text] [Related]
45. The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development.
Uçar I; Ertekin T; Nisari M; Ceylan D; Al Ö; Ülger H
Folia Morphol (Warsz); 2016; 75(2):257-263. PubMed ID: 26711647
[TBL] [Abstract][Full Text] [Related]
46. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
47. Acute acneiform eruption induced by interferon beta-1b during treatment for multiple sclerosis.
Rosa DJ; Matias Fde A; Cedrim SD; Machado RF; Sá AA; Silva VC
An Bras Dermatol; 2011; 86(2):336-8. PubMed ID: 21603818
[TBL] [Abstract][Full Text] [Related]
48. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
[TBL] [Abstract][Full Text] [Related]
49. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
[TBL] [Abstract][Full Text] [Related]
50. [Current status of interferon beta-1b in multiple sclerosis therapy].
Hartung HP
Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
[TBL] [Abstract][Full Text] [Related]
51. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
Keating MM; Ostby PL
J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
[TBL] [Abstract][Full Text] [Related]
52. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
53. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.
Tenembaum SN; Banwell B; Pohl D; Krupp LB; Boyko A; Meinel M; Lehr L; Rocak S; Cantogno EV; Moraga MS; Ghezzi A;
J Child Neurol; 2013 Jul; 28(7):849-56. PubMed ID: 23666046
[TBL] [Abstract][Full Text] [Related]
54. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
Walther EU; Dietrich E; Hohlfeld R
Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
[TBL] [Abstract][Full Text] [Related]
55. Liver injury associated with the beta-interferons for MS.
Francis GS; Kaplowitz N; Alteri E
Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
[No Abstract] [Full Text] [Related]
56. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
57. Interferon beta-1a in children with multiple sclerosis is well tolerated.
Waubant E; Hietpas J; Stewart T; Dyme Z; Herbert J; Lacy J; Miller C; Rensel M; Schwid S; Goodkin D
Neuropediatrics; 2001 Aug; 32(4):211-3. PubMed ID: 11571702
[TBL] [Abstract][Full Text] [Related]
58. Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Gobbi C; Zecca C; Linnebank M; Müller S; You X; Meier R; Borter E; Traber M
Eur Neurol; 2013; 70(1-2):35-41. PubMed ID: 23689307
[TBL] [Abstract][Full Text] [Related]
59. Arthritis during interferon beta-1b treatment in multiple sclerosis.
Altintas A; Alici Y; Melikoğlu M; Siva A
Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
[TBL] [Abstract][Full Text] [Related]
60. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
Almeida L; Neves M; Cardoso E; Melo A
J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
